Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy



Status:Completed
Conditions:Neurology, Epilepsy
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - Any
Updated:1/17/2018
Start Date:June 2010
End Date:January 2013

Use our guide to learn which trials are right for you!

Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy

The purpose of this study is to assess the safety and tolerability of intravenous (IV)
carbamazepine (CBZ) administered as multiple 15 minute infusions and a single 5 minute
infusion to adult patients with epilepsy on stable higher doses of oral CBZ.

This was a phase III, multicenter, open-label study designed to assess the safety and
tolerability of intravenously administered CBZ in adult patients with epilepsy. This study
included a 28 day Lead-in Period, a Confinement Period (up to 7 days and 6 nights) and a 28
day Follow-up Period.

Patients began confinement on Day -1 of the trial, continuing to take their oral CBZ as
prescribed by the investigator. On the morning of Day 0, Day 4, and Day 17, patients began
the 24hr urine collection for evaluation of urinary biomarkers. All patients temporarily
discontinued their prescribed oral CBZ and begin IV CBZ administration on the morning of Day
1, continuing administrations every 6 hours (Q6h) through the morning of Day 4.

Inclusion Criteria:

1. The patient or legal representative must be able to read, understand, sign and date
the IRB approved Informed Consent Form and HIPAA Authorization prior to study
participation.

2. The patient is a man or a non-pregnant woman who is at least 18 years of age.

3. If a woman:

- Patient is either not of childbearing potential, defined as postmenopausal for at
least 1 year or surgically sterile (bilateral tubal ligation, bilateral
oophorectomay or hysterectomy), or if childbearing potential, must comply with a
method of birth control acceptable to the investigator during the study, for at
least 28 days prior to Day 1 and for 28 days following completion of the study.

- Patient is not breastfeeding.

- Patient of childbearing potential must have a negative serum pregnancy test at
Day -28 and a negative urine pregnancy test or serum pregnancy test at Day -1.

4. The patient is diagnosed with any of the approved epilepsy indications for CBZ:

- Partial seizures with complex symptomatology (psychomotor, temporal lobe)

- Generalised tonic clonic seizures (GTCS) (grand mal): myoclonic, clonic, tonic,
tonic-clonic, atonic

- Mixed seizure patterns that include the above, or other partial or generalised
seizures (except absence seizures - please see exclusion point number 12)

5. The patient is receiving a stable dose of oral CBZ (tablet or capsule formulation) of
1200 mg/day to 2000 mg/day, for a minimum of 14 days prior to Day -28.

6. The patient is receiving a constant dose of all other concomitant medications used for
chronic conditions, (including OTC medications and herbal supplements) for a minimum
of 28 days prior to Day 1.

7. The patient is not expected to have any change in his/her baseline AED treatment
during the treatment period.

8. The patient is able to comply with maintaining an accurate Seizure and antiepileptic
drug diary.

9. The patient is able to comply with all study procedures including complying with
protocol determined dosing intervals, confinement at the investigative site for up to
6 nights and 7 days, and agrees to participate in the entire study.

Exclusion Criteria:

1. The patient has a known hypersensitivity to CBZ, Captisol, or to any of the tricyclic
compounds, such as amitriptyline, trimipramine, imipramine; oxacarbazepine, phenytoin,
or their analogues or metabolites.

2. The patient has a history of previous bone marrow depression.

3. The patient has a history of intolerance to IV administration of medication.

4. The patient is pregnant or lactating.

5. The patient is being treated with a monoamine oxidase (MAO) inhibitor.

6. The patient is using oral, intramuscular, or any other hormone delivery method as
their primary form of birth control.

7. The patient has an ECG with corrected QT interval by Fridericia's correction formula
(QTcF) greater than 450 msec at Screening or Day -1.

8. The patient has a screening ALT, AST or bilirubin >=3 times the upper limit of normal.

9. The patient has an estimated ClCR (based of Cockcroft-Gault) of <50 ml/min.

10. The patient has had a clinically significant illness/infection or has had any surgical
procedure within 30 days prior to Screening.

11. The patient has a significant history of cardiac, renal, neurologic (other than
epilepsy), psychiatric, oncologic, endocrinologic, metabolic, or hepatic disease,
which would adversely affect their participation in this study.

12. The patient is receiving oral CBZ for absence seizures.

13. The patient has had an episode of status epilepticus within 4 weeks of Screening.

14. The patient has a history of severe or serious adverse reactions to CBZ (for example,
aplastic anemia, agranulocytosis, SJS.

15. The patient has taken or used any investigational drug or device in the 30 days prior
to Screening.

16. The patient has previously been administered IV CBZ in a previous clinical trial (for
example OV-1015).

17. The patient has a urine toxicology screen positive for phencyclidine, benzodiazepines
(unless due to the patient's concomitant AEDs), cannabinoids, cocaine, amphetamines,
opiates, barbiturates (unless due to the patient's concomitant AEDs), or alcohol at
Screening or Day -1.

18. The patient has had a diagnosis of drug or alcohol abuse within the past year prior to
Screening.

19. The patient has had significant blood loss (>500 mL) or donation within 14 days of
Screening.

20. The patient has a history of poor oral CBZ compliance.

21. The patient is participating in a weight loss or nicotine cessation program.

22. The patient has a history of increased intraocular pressure or is on medication for
glaucoma.

23. The patient is considered by the investigator to be an unsuitable candidate for the
study, which may include an increase in the frequency, severity and duration of
seizures during the Pre-Treatment Period (Days -28-0).

24. The patient has previously participated in this study.

25. The patient is a member of the site personnel or their immediate families.
We found this trial at
29
sites
?
mi
from
New York, NY
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Bethesda, Maryland 20817
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bronx, New York 10467
?
mi
from
Bronx, NY
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
?
mi
from
Chesterfield, MO
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
(312) 996-4350
University of Illinois at Chicago A major research university in the heart of one of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Dallas, Texas 75230
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80204
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Houma, LA
Click here to add this to my saved trials
Little Rock, Arkansas 72205
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
New Orleans, Louisiana 70114
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19140
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85054
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Richmond, Virginia 23298
?
mi
from
Richmond, VA
Click here to add this to my saved trials
1000 Westgate Drive
Saint Paul, Minnesota 55114
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
801 N Rutledge St
Springfield, Illinois 62702
(217) 545-8000
Southern Illinois University School of Medicine At SIU School of Medicine, research includes biologically oriented...
?
mi
from
Springfield, IL
Click here to add this to my saved trials
750 East Adams Street
Syracuse, New York 13210
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
2401 S. 31st Street
Temple, Texas 76508
254-724-2111
Scott & White Memorial Hospital When Arthur C. Scott, MD, and Raleigh R. White Jr.,...
?
mi
from
Temple, TX
Click here to add this to my saved trials
Torrance, California 90502
?
mi
from
Torrance, CA
Click here to add this to my saved trials
Wichita, Kansas 67214
?
mi
from
Wichita, KS
Click here to add this to my saved trials
Winfield, Illinois 60190
?
mi
from
Winfield, IL
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials